Myocardial hypertrophy is improved with berberine treatment via long non-coding RNA MIAT-mediated autophagy

Zeng, Zhicong; Pan, Yan; Wu, Wei; Li, Liang; Wu, Zhenru; Zhang, Yuangui; Deng, Bin; Wei, Shanyan; Zhang, Weiwei; Lin, Fengxia; Song, Yong Jung

doi:10.1111/jphp.13170

Cited by 26 publications

(19 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, berberine 147 was found to increase autophagic gene expression by reducing lncRNA MIAT expression in vivo and inactivating AMPK/mTOR pathway in vitro. Eisenberg et al 148 showed that spermidine feeding could extend the lifespan of the mice and protect against overloaded cardiac hypertrophy in the murine model due to enhanced autophagy and mitophagy.…”

Section: Natural Products In Preventing Pathological Cardiac Hypertmentioning

confidence: 97%

Autophagy and cardiac diseases: Therapeutic potential of natural products

Liu

et al. 2020

Medicinal Research Reviews

View full text Add to dashboard Cite

The global incidence of cardiac diseases is expected to increase in the coming years, imposing a substantial socioeconomic burden on healthcare systems. Autophagy is a tightly regulated lysosomal degradation mechanism important for cell survival, homeostasis, and function. Accumulating pieces of evidence have indicated a major role of autophagy in the regulation of cardiac homeostasis and function. It is well established that dysregulation of autophagy in cardiomyocytes is involved in cardiac hypertrophy, myocardial infarction, diabetic cardiomyopathy, and heart failure. In this sense, autophagy seems to be an attractive therapeutic target for cardiac diseases. Recently, multiple natural products/phytochemicals, such as resveratrol, berberine, and curcumin have been shown to regulate cardiomyocyte autophagy via different pathways. The autophagy‐modifying capacity of these compounds should be taken into consideration for designing novel therapeutic agents. This review focuses on the role of autophagy in various cardiac diseases and the pharmacological basis and therapeutic potential of reported natural products in cardiac diseases by modifying autophagic processes.

show abstract

Section: Natural Products In Preventing Pathological Cardiac Hypertmentioning

confidence: 97%

Autophagy and cardiac diseases: Therapeutic potential of natural products

Liu

et al. 2020

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Zeng et al. demonstrated that cardiomyocyte autophagy was enhanced by berberine-induced MIAT knockdown, which further contributed to the improved cardiomyocyte contractility ( Zeng et al, 2019 ). Therefore, development of a small molecule which can specifically target MIAT could be our next aim.…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p

Xiao

Zheng²,

Chen

et al. 2021

iScience

View full text Add to dashboard Cite

Summary Diabetic cardiomyopathy (DCM) is one of the most common complications of diabetes without effective treatment options. Its pathogenesis is complex and remains unclear. Long non-coding RNA (lncRNA) MIAT allele has been reported to be enriched in DCM patients and activate a pyroptosis program in hypoxia-induced H9c2 cells. Thus, whether MIAT played a role in DCM pyroptosis remains to be clarified. In the study, the expression of MIAT was found elevated in the serum of diabetic patients, as well as in high-glucose induced cardiomyocytes and diabetic mice. Further, the expression levels of CASP1 and pyroptosis correlation factors (IL-1 and IL-18) were downregulated after silencing MIAT. Through modeling and validation experiments, we then confirmed that the MIAT-miR-214-3p-CASP1 axis serves as an essential point in pyroptosis of DCM mice. These results suggested that silencing MIAT would be a potential treatment strategy for DCM.

show abstract

“…Still, another group described their work on evaluating the effects of berberine, an effective natural supplement compound extracted from several plants, on CH in a rat model with constriction of abdominal aorta and H9C2 cells stimulated with AngII to induce cardiomyocyte hypertrophy [58]. They depicted that berberine significantly relives CH and cardiomyocyte enlargement and expression of hypertrophy marker proteins.…”

Section: Lncr-miat and Cardiac Hypertrophymentioning

confidence: 99%

MIAT, a potent CVD-promoting lncRNA

Zhang

Yang

2021

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The initial identification of long non-coding RNA myocardial infarction associated transcript (MIAT) as a genetic risk factor of myocardial infarction has made this lncRNA (designated as lncR-MIAT here) a focus of intensive studies worldwide. Emerging evidence supports that lncR-MIAT is susceptible in its expression to multiple deleterious factors like angiotensin II, isoproterenol, hypoxia, and infection and is anomaly overexpressed in serum, plasma, blood cells and myocardial tissues under a variety of cardiovascular conditions including myocardial infarction, cardiac hypertrophy, diabetic cardiomyopathy, dilated cardiomyopathy, sepsis cardiomyopathy, atrial fibrillation and microvascular dysfunction. Experimental results consistently demonstrated that upregulation of lncR-MIAT plays active roles in the pathological processes of the cardiovascular system and knockdown of this lncRNA effectively ameliorates the adverse conditions. The available data revealed that lncR-MIAT acts through multiple mechanisms such as competitive endogenous RNA, natural antisense RNA and RNA/ protein interactions. Moreover, the functional domains of lncR-MIAT accounting for certain specific cellular functions of the full-length transcript have been identified and characterized. These insights will not only tremendously advance our understanding of lncRNA biology and pathophysiology, but also offer good opportunities for more innovative and precise design of agents that have the potential to be developed into new drugs for better therapy of cardiovascular diseases (CVDs) in the future. Herein, we provide an overview of lncR-MIAT, focusing on its roles in cardiovascular diseases, underline the unique cellular/molecular mechanisms for its actions, and speculate the perspectives about the translational studies on the potential diagnostic and therapeutic applications of lncR-MIAT.

show abstract

Myocardial hypertrophy is improved with berberine treatment via long non-coding RNA MIAT-mediated autophagy

Cited by 26 publications

References 58 publications

Autophagy and cardiac diseases: Therapeutic potential of natural products

Autophagy and cardiac diseases: Therapeutic potential of natural products

Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p

MIAT, a potent CVD-promoting lncRNA

Contact Info

Product

Resources

About